NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading SRZN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, but it is in the early stages of advancing its product pipeline.
The market seems to have priced in a challenging outlook given the company's recent earnings misses and loss-making status. However, the healthcare sector backdrop has improved, which may provide some support.
Fundamentals are likely to remain under pressure in the near term due to the elevated risk of further earnings misses. Management is focused on advancing its pipeline, but recent results have not met expectations.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as well as potential rate cuts by the Fed. Positive developments in SRZN's pipeline and successful execution of management priorities will also be crucial.
In the next 1 to 3 years, SRZN's performance will depend heavily on sector trends and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings results will show if the company can recover from the recent earnings miss.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue decline year over year.
Why it matters: Submitting the IND application is a key step in advancing SZN-8141. It shows progress in the drug development process.
Confirms:Surrozen submits the IND application for SZN-8141 to the FDA in the second half of 2026.
Disproves:The IND application for SZN-8141 is delayed beyond the second half of 2026.
Why it matters: If sector growth slows, it could hurt Surrozen's performance and outlook.
Confirms:Sector revenue growth has been below its median for two quarters in a row.
Disproves:Sector revenue growth remains above its median.
Why it matters: R&D spending is crucial for growth. A drop could signal deeper issues.
Confirms:R&D spending drops below 20% of revenue.
Disproves:R&D spending remains above 24% of revenue.
Why it matters: The health care sector is maturing. If revenue growth speeds up, it could help Surrozen's outlook.
Confirms:Sector revenue growth is speeding up again. It is now close to 12% or higher each year.
Disproves:Sector revenue growth remains below 9% year over year.
Why it matters: The upcoming earnings results will show if the company can recover from its recent earnings miss. Investors will look for signs of improvement.
Confirms:Earnings results show revenue growth of at least 5% compared to last quarter.
Disproves:Earnings results show revenue decline or flat growth compared to last quarter.
Why it matters: Good early data would show SZN-8141 could help treat eye diseases. This might bring more interest and money.
Confirms:Surrozen will share good early data on SZN-8141 at upcoming science meetings.
Disproves:Preclinical data does not support the efficacy claims for SZN-8141.
Why it matters: More money from this partnership shows SZN-413 is developing well. This may help the company’s finances.
Confirms:Revenue from Boehringer Ingelheim is over $5.0 million in the next few quarters.
Disproves:Revenue from Boehringer Ingelheim stays the same or goes down.
Why it matters: Having a lot of cash helps keep the company running and developing. A big drop could worry investors.
Confirms one read:Cash and cash equivalents rise from $106.9 million in Q1 2026 by the next earnings report.
Confirms the other:Cash and cash equivalents fall from $106.9 million in Q1 2026 by the next earnings report.
